The St. Jude Medical Trifecta valve is a novel aortic biological prosthesis that incorporates several design features, including a true supra-annular sewing cuff, a stent design that maximizes valve hemodynamics while minimizing leaflet stresses and an ethanol-based anti-calcification technology. This study establishes safety, early clinical and hemodynamic performance of the Trifecta valve.
BACKGROUND
The St. Jude Medical Trifecta valve is a novel aortic biological prosthesis that incorporates several design features, including a true supra-annular sewing cuff, a stent design that maximizes valve hemodynamics while minimizing leaflet stresses and an ethanol-based anti-calcification technology. This study establishes safety, early clinical and hemodynamic performance of the Trifecta valve. Figure 1 shows the average mean gradients collected on patients by valve size at 1 year.
METHODS

RESULTS IN CONTEXT
Based on the results of the current study, the Trifecta valve represents significant progress in the development of a stented bioprosthesis with near physiologic hemodynamics. The nearly cylindrical opening of the prosthesis on systole provides gradients and effective Brief Summary: Please review the Instructions for Use prior to using these devices for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.
T R I F E C TA ™ T I S S U E V A LV E
Indications:
The Trifecta Valve is indicated as a replacement for a diseased, damaged, or malfunctioning native or prosthetic aortic heart valve. Adverse events potentially associated with the use of bioprosthetic heart valves include: angina, cardiac arrhythmias, endocarditis, heart failure, hemolysis, hemolytic anemia, hemorrhage, leak (transvalvular or perivalvular), myocardial infarction, nonstructural dysfunction (entrapment by pannus or suture, inappropriate sizing or positioning, or other), prosthesis regurgitation, stroke, structural deterioration (calcification, leaflet tear, perforation, or other), thromboembolism and valve thrombosis. It is possible that these complications could lead to reoperation, explantation, permanent disability or death. The presence of severe PPM has been shown in several studies to lead to significantly poorer long-term survival in a variety of patient groups. In series with older generation prostheses and varying definitions of mismatch have been reported up to 51%.
In the current study, the Trifecta valve had an extremely low rate of paravalvular leak despite having a highly efficient low-profile sewing ring, indicative of ease of implantability. There was also minimal valvular regurgitation even in larger sizes, a problem more common in previous generation surgical pericardial valves.
CONCLUSIONS
In summary, the St. Jude Medical Trifecta valve is a unique pericardial bioprosthesis with design elements that provide excellent hemodynamic performance while providing ease of implantation. Long-term follow-up continues in order to confirm the promising results of this innovative bioprosthesis.
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